Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Staines, 27th March 2012. ASTELLAS PHARMA EUROPE Ltd., the European subsidiary of Tokyo – based Astellas Pharma Inc.(Tokyo:4503) today announced the submission of a Market Authorisation...
Astellas Pharma Inc. (TSE:4503; Headquarters, Tokyo; President & CEO, Yoshihiko Hatanaka; ”Astellas”) and UMN Pharma Inc. (Headquarters, Akita; CEO, Shu-ichi Kanazashi; ”UMN”) today...
Sanofi (Headquarters: Paris, France) and Astellas Pharma Inc. (Headquarters: Tokyo, President and CEO: Yoshihiko Hatanaka) announced today that the two companies agreed to dissolve sanofi-aventis...
Read more about Sanofi and Astellas to dissolve sanofi-aventis Yamanouchi Pharmaceutical Inc.
Tokyo, February 20, 2012 - Astellas Pharma Inc. (“Astellas”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) and Sanwa Kagaku Kenkyusho Co., Ltd. (“SKK”; Headquarters: Nagoya;...
Astellas and UCB partner to bring certolizumab pegol to rheumatoid arthritis patients in Japan UCB files certolizumab pegol for marketing authorisation with the Japanese Ministry of Health, Labour...
Tokyo, Japan, January 19, 2012 – The Astellas Asia-Oceania Foundation announced that it donated U.S. dollar 20,000 to the Philippine Urological Association for relief efforts in the Philippines...
Read more about Astellas Asia-Oceania Foundation Supports Philippine Typhoon Relief Efforts
TOKYO, JAPAN and SANTA CLARA, CA - January 17, 2012 - Astellas Pharma Inc. (Tokyo: 4503) and XenoPort, Inc. (NASDAQ: XNPT) announced today that Regnite® (gabapentin enacarbil) has received...
Follow us
